MSResearcher profile · from public sources
Marion Subklewe
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.
HemaSphere, Oct 2026
Publication
Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy.
Bone marrow transplantation, Sept 2026
Publication
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.
Journal for immunotherapy of cancer, Sept 2026
Publication
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.
Bone marrow transplantation, Aug 2026
Publication
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.
Intensive care medicine, Jun 2026
Publication
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.
Leukemia, Jun 2026
Publication
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.
Blood, Mar 2026
Publication
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.
Blood advances, Feb 2026
Publication
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.
Journal for immunotherapy of cancer, Dec 2025
Publication
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.
Blood cancer journal, Aug 2025
Publication
Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis.
Infection, May 2025
Publication
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.
Cancer immunology, immunotherapy : CII, May 2025
Publication
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leukemia, Mar 2025
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Christopher S Hourigan directly.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error